First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Autor: Rupa Narayan, Ana Alfonso Piérola, William B. Donnellan, Antonieta Molero Yordi, Maher Abdul‐Hay, Uwe Platzbecker, Marion Subklewe, Tapan Mahendra Kadia, Juan Manuel Alonso‐Domínguez, James McCloskey, Kathryn Bradford, Martin Curtis, Nikki Daskalakis, Christina Guttke, Karim Safer, Brett Hiebert, Joseph Murphy, Xiang Li, Ken Duchin, Daniel Esteban

Publikováno v: Clinical and Translational Science, Vol 17, Iss 3, Pp n/a-n/a (2024)

Abstract Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ‐67571244, was assessed to identify the maximum tol

Externí odkaz: https://doaj.org/article/274473cdc5184c6596ff63a5c9aab2bf

Supplementary Figures S1-S2 from Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

Autor: Amit Verma, Aditi Shastri, Britta Will, Ulrich Steidl, Ira Braunschweig, Kira Gritsman, Noah Kornblum, Mendel Goldfinger, Nishi Shah, R. Alejandro Sica, Ioannis Mantzaris, Mimi Kim, Kith Pradhan, Mohammed Kazemi, Sakshi Jasra, Cassady Remy, Karen Fehn, Prafulla Bhagat, Jesus Berdeja, William B. Donnellan, Abdulraheem Yacoub, Suman Kambhampati, Jesus D. Gonzalez-Lugo

Supplemental Figure 1. Overall Survival Responders vs Non-Responders Supplemental Figure 2. Overall Survival Among Groups

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3cf496686dd19fa5b10d5494cc344ad
https://doi.org/10.1158/1078-0432.22489251

Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial

Autor: Jesus D, Gonzalez-Lugo, Suman, Kambhampati, Abdulraheem, Yacoub, William B, Donnellan, Jesus, Berdeja, Prafulla, Bhagat, Karen, Fehn, Cassady, Remy, Sakshi, Jasra, Mohammed, Kazemi, Kith, Pradhan, Mimi, Kim, Ioannis, Mantzaris, R Alejandro, Sica, Nishi, Shah, Mendel, Goldfinger, Noah, Kornblum, Kira, Gritsman, Ira, Braunschweig, Ulrich, Steidl, Britta, Will, Aditi, Shastri, Amit, Verma

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research.

Thrombocytopenia is a serious complication of MDS associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalido

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::103d2e99cdc4bb03816a9caa11ac89bd
https://pubmed.ncbi.nlm.nih.gov/36255372

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Autor: Giulia Benevolo, Christian Hertig, Gregory Hooper, Srdan Verstovsek, Natalie Dimier, Stephen Couban, William B. Donnellan, Steffen Koschmieder, Vikram Malhi, Maneesh Tandon, Jennifer Cultrera, Francesco Passamonti

Publikováno v: Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-4 (2018)
Journal of hematology & oncology 11(1), 122 (2018). doi:10.1186/s13045-018-0661-x

Background The JAK inhibitor (JAKi) ruxolitinib is standard treatment for myelofibrosis (MF), but some patients are unresponsive. Pre-clinical and clinical data suggest that addition of a Hedgehog pathway inhibitor (HPI) to ruxolitinib might improve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b349a39d156c81fe6d7e834240f93f43
http://link.springer.com/article/10.1186/s13045-018-0661-x

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Autor: Esprit Ma, Maika Onishi, Huan Jin, Pankit Vachhani, Evelyn M. Flahavan, Brannon Flores, Cat N. Bui, Anda Gershon, Grace Ku, Weize Huang, Jonathan A. Abbas, William B. Donnellan, Melissa Montez, Tao Xu

Publikováno v: Blood. 138:2290-2290

Background: Ven+HMA is now a standard treatment (Tx) for newly diagnosed (ND) AML in patients (pts) aged ≥75 years (y), or with comorbidities precluding intensive chemotherapy. The Phase 3 VIALE-A trial demonstrated clinical benefit and longer over

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4b6fa272dbd8d2507fb1e4a69a85269
https://doi.org/10.1182/blood-2021-147851